Abstract: Pharmaceutical composition comprising growth-hormone releasing peptide 6 (GHRP-6), tartrate buffer at pH 5.0-6.0, and trehalose as stabilizing agent, as well as the use of said composition for the manufacture of a medicament. The invention also provides a kit of parts comprising said pharmaceutical composition and a method of treatment of an individual in need thereof, which entails the administration of a therapeutically effective amount of the pharmaceutical composition comprising of GHRP-6, tartrate buffer at pH 5.0-6.0 and trehalose.

Abstract: The invention discloses a soybean plant, or a part of said plant comprising the transgenic event CIGBDt-Def1 or the transgenic event CIGBIs-Def5, as well as a method for the detection of those events in soybean samples. It also provides a seed from a soybean plant comprising said transgenic events, and products obtained from a plant, or from soybean seeds, comprising one of said events. In addition, the invention is related to a method for the production of soybean plants resistant to glyphosate, and to diseases caused by fungi or oomycetes, comprising the introduction of one of the mentioned transgenic events in the genome of said plants. The increase in the yield of a soybean crop in the field can be achieved with the transgenic events of the invention.

Abstract: Chimeric antigen comprising multimeric aggregates of the extracellular domain of the programmed death ligand 1 (PD-L1) with a reduced binding capacity to the PD-1 and CD80 receptors as compared to the native PD-L1 molecule. The invention further discloses pharmaceutical compositions including said chimeric antigen and at least a pharmaceutically acceptable vaccine adjuvant. The chimeric antigen is used for the manufacturing of a drug to treat cancer or its metastases. The invention also discloses a method of treating cancer or its metastases in a subject in need thereof, characterized by the administration of a therapeutically effective amount of the pharmaceutical composition comprising the chimeric antigen described herein.

Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.

Abstract: The invention discloses a soybean plant, or a part of said plant comprising the transgenic event CIGBDt-Def1 or the transgenic event CIGBIs-Def5, as well as a method for the detection of those events in soybean samples. It also provides a seed from a soybean plant comprising said transgenic events, and products obtained from a plant, or from soybean seeds, comprising one of said events. In addition, the invention is related to a method for the production of soybean plants resistant to glyphosate, and to diseases caused by fungi or oomycetes, comprising the introduction of one of the mentioned transgenic events in the genome of said plants. The increase in the yield of a soybean crop in the field can be achieved with the transgenic events of the invention.

Abstract: Polypeptides comprising functional mutants of an isoform of the human vascular endothelial growth factor A (VEGF-A) folded in a non-natural re-arrangement, where the second and fourth cysteine of the mutant's polypeptide chain is only forming intramolecular bridges, while the seventh and eight are only part of intermolecular bonds. The invention further comprises antigenic preparations containing at least one of these polypeptides, and the pharmaceutical compositions comprising such antigenic preparations and vaccine adjuvants. The antigenic preparations according to the invention are used in the manufacturing of a drug, for the treatment of diseases related to the increment of angiogenesis, inflammation, and immunosuppression, as well as for the restoration of the immune system.

Abstract: The present invention is related to the use of the growth hormone releasing peptide-6 (GHRP-6) for the manufacture of a late cardioprotective and cardiac restoration medicament. Said late cardioprotective and cardiac restoration medicament comprises GHRP-6 and a pharmaceutically acceptable excipient or vehicle. It also provides a method for the treatment of a disease that involves a low cardiac output, wherein a therapeutically effective amount of a late cardioprotective and cardiac restoration medicament comprising GHRP-6 is administered to a subject in need. Said medicament allows treating in a late manner, even days later, the myocardium that suffered episodes of stunning, hibernation, ischemia and its consequences thereof.

Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.

Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.

Abstract: The present invention reveals the use of epidermal growth factor (EGF) for the manufacture of an injectable medicament for the treatment of a diabetic foot ulcer (DFU), in a patient without criteria of amputation of the affected limb at the time of the clinical evaluation, wherein the medicament comprising EGF is administered by intralesional infiltration in said ulcer once a week. Moreover, it provides a pharmaceutical composition comprising EGF, for the treatment of a DFU in a patient, where the composition is administered once a week. The invention comprises a method for the treatment of a DFU in a patient, without criteria of amputation of the affected limb at the time of the clinical evaluation, comprising administering EGF to the patient, by intralesional infiltration in the ulcer base once a week.

Abstract: Solid composition for agricultural or veterinary use comprising a mixture of bacterial concentrate of the strain C-924 and a commercially available culture medium or organic amendment, an antifoaming substance, sucrose, and having less than 12% residual moisture. The components of the formulation allow an adequate wettability of the solid final product, and its prolonged stability at storage temperature of 2 to 8° C. The invention discloses the use of the solid composition in the control of pathogens of plants and animals, and in the stimulation of seed germination and plant growth.

Abstract: The present invention is related to the use of the growth hormone releasing peptide-6 (GHRP-6) for the manufacture of a late cardioprotective and cardiac restoration medicament. Said late cardioprotective and cardiac restoration medicament comprises GHRP-6 and a pharmaceutically acceptable excipient or vehicle. It also provides a method for the treatment of a disease that involves a low cardiac output, wherein a therapeutically effective amount of a late cardioprotective and cardiac restoration medicament comprising GHRP-6 is administered to a subject in need. Said medicament allows treating in a late manner, even days later, the myocardium that suffered episodes of stunning, hibernation, ischemia and its consequences thereof.

Abstract: The invention discloses a pharmaceutical combination comprising epidermal growth factor (EGF) and the hexapeptide secretagogue GHRP6, useful for the restoration of brain damage, by stimulating mechanisms of differentiation and neuronal specialization in undifferentiated cells residing in the central nervous system or in neuronal cells. The invention also encompasses the use of the above mentioned biomolecules in the manufacture of a pharmaceutical combination for the restoration of brain damage. In addition, the invention provides a method of restoring brain damage in which a therapeutically effective amount of a pharmaceutical combination comprising EGF and GHRP6 is administered to a patient in need thereof. The efficacy of the pharmaceutical combination has a broad therapeutic window: it is independent of whether the pharmacological intervention occurs in the first or further hours after the brain damage, which broadens the therapeutic window.

Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.

Abstract: The present invention is related to a stereotaxic frame for extremities that ensures that the extremity position is fixed and reproducible; keeping the same geometric conditions of the measurement or treatment devices regards the extremity, or part thereof, during the study or therapy. The frame comprises a positioning and fixing holder for the extremity and a measuring or treatment system, that includes a geometric locus where the measurement or treatment device is allocated, ensuring that the relative position of said device regards the region of the extremity under examination or treatment is reproducible.

Abstract: The present invention discloses structurally constrained synthetic peptides that have been optimized for the formation of a beta hairpin structure. Said peptides are able to inhibit or attenuate Dengue virus (DENV) infections. The invention also discloses pharmaceutical compositions containing these synthetic peptides, which are useful for the prevention and/or treatment of DENV-caused infections. Likewise, the invention disclosed a method for treating infections caused by this virus.

Abstract: The invention relates to chimeric vaccine antigens against hepatitis C virus (HCV) comprising selected regions of different antigens of said virus, which are placed in a pre-determined order inside the polypeptide. In addition, said chimeric antigens can include artificially formed specific epitopes for auxiliary T helper lymphocytes. The chimeric antigens and the resulting vaccine compositions are suitable for use in medicine and the pharmaceutical industry, as well as being suitable for prophylactic and/or therapeutic use against HCV. The vaccine compositions of the invention generate a powerful, broad-spectrum immune response against different antigens of the virus, with a minimum number of components.

Abstract: The present invention discloses structurally constrained synthetic peptides that have been optimized for the formation of a beta hairpin structure. Said peptides are able to inhibit or attenuate Dengue virus (DENV) infections. The invention also discloses pharmaceutical compositions containing these synthetic peptides, which are useful for the prevention and/or treatment of DENV-caused infections. Likewise, the invention disclosed a method for treating infections caused by this virus.

Abstract: The present invention comprises cyclic peptides bearing antitumor and antiangiogenic properties, as well as their corresponding pharmaceutically-suitable salts and also pharmaceutical compositions containing it. These cyclic peptides are used to prepare medicines for human and/or veterinary therapeutics, and additionally in diagnosis. These compounds can be used to detect, monitor and/or control a range of cellular proliferation-related disorders, such as oncological diseases and undesired angiogenesis. Moreover, they can be included as part of controlled release systems, and used more precisely in the field of nanobiotechnology, either because of their self-assembly capacity or as part of other systems.

Abstract: The invention relates to chimeric vaccine antigens against hepatitis C virus (HCV) comprising selected regions of different antigens of said virus, which are placed in a pre-determined order inside the polypeptide. In addition, said chimeric antigens can include artificially formed specific epitopes for auxiliary T helper lymphocytes. The chimeric antigens and the resulting vaccine compositions are suitable for use in medicine and the pharmaceutical industry, as well as being suitable for prophylactic and/or therapeutic use against HCV. The vaccine compositions of the invention generate a powerful, broad-spectrum immune response against different antigens of the virus, with a minimum number of components.